Design, synthesis and biological evaluation of a new thieno[2,3-
Antineoplastic Agents
/ chemical synthesis
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Cell Proliferation
/ drug effects
Dose-Response Relationship, Drug
Drug Design
Drug Resistance, Neoplasm
/ drug effects
Drug Screening Assays, Antitumor
Female
Humans
Molecular Docking Simulation
Molecular Structure
Pyrimidines
/ chemical synthesis
Structure-Activity Relationship
Tamoxifen
/ pharmacology
Urea
/ analogs & derivatives
Thieno[2,3-d]pyrimidine-based urea derivative
VEGFR-2 kinase
anti-inflammatory
antiangiogenesis
apoptosis makers
breast cancer
Journal
Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
10
4
2021
Statut:
ppublish
Résumé
Breast cancer (BC) and endocrine resistance to chemotherapy are challenging problems where angiogenesis plays fundamental roles. Thus, targeting of VEGFR-2 signalling pathway has been an attractive approach. In this study, we synthesised a new sorafenib analogue, thieno[2,3-
Identifiants
pubmed: 32781854
doi: 10.1080/14756366.2020.1804383
pmc: PMC7470147
doi:
Substances chimiques
Antineoplastic Agents
0
Pyrimidines
0
thieno(2,3-d)pyrimidine
0
Tamoxifen
094ZI81Y45
Urea
8W8T17847W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1641-1656Références
J Pharmacol Exp Ther. 2011 Apr;337(1):155-61
pubmed: 21205925
Cell Mol Life Sci. 2020 Feb;77(4):559-572
pubmed: 31471681
Asian Pac J Cancer Prev. 2018 Jul 27;19(7):1971-1975
pubmed: 30051683
Nitric Oxide. 2001 Feb;5(1):62-71
pubmed: 11178938
Sci Rep. 2018 Jun 11;8(1):8859
pubmed: 29891854
Int J Oncol. 2014 Nov;45(5):2167-75
pubmed: 25175082
Ann Transl Med. 2014 Dec;2(12):123
pubmed: 25568876
J Med Chem. 2013 Feb 28;56(4):1641-55
pubmed: 23362959
J Exp Clin Cancer Res. 2018 Nov 1;37(1):266
pubmed: 30382874
Cell Mol Life Sci. 2011 Dec;68(23):3853-68
pubmed: 21744247
Eur J Med Chem. 2000 Dec;35(12):1065-79
pubmed: 11248405
J Cell Physiol. 2012 Apr;227(4):1319-25
pubmed: 21604268
Arch Biochem Biophys. 1959 May;82(1):70-7
pubmed: 13650640
Anticancer Drugs. 2004 Sep;15(8):787-93
pubmed: 15494641
Biotechniques. 2005 Jan;38(1):73-83
pubmed: 15679089
Chem Pharm Bull (Tokyo). 2016;64(5):490-6
pubmed: 27150481
Acta Pharmacol Sin. 2015 Feb;36(2):241-51
pubmed: 25557114
J Pharm Biomed Anal. 2008 Jan 22;46(2):362-7
pubmed: 18309574
Cell Cycle. 2013 Jun 1;12(11):1722-31
pubmed: 23656786
Bioorg Med Chem Lett. 2013 May 15;23(10):2962-7
pubmed: 23562241
Int J Mol Sci. 2014 Dec 11;15(12):23024-41
pubmed: 25514409
Mol Biol Rep. 2020 Mar;47(3):2061-2071
pubmed: 32072404
Bioorg Med Chem. 2010 Oct 15;18(20):7260-73
pubmed: 20833055
Oncol Lett. 2017 Nov;14(5):5865-5870
pubmed: 29113219
J Egypt Natl Canc Inst. 2013 Dec;25(4):181-91
pubmed: 24207090
J Exp Med. 2012 Feb 13;209(2):211-5
pubmed: 22330683
Asian J Androl. 2010 Jul;12(4):527-34
pubmed: 20473320
Breast Cancer Res Treat. 2013 Aug;141(1):67-78
pubmed: 23963659
Bioorg Med Chem. 2004 Jul 15;12(14):3891-901
pubmed: 15210156
Biochem Biophys Res Commun. 2017 Aug 26;490(3):780-785
pubmed: 28645612
Org Biomol Chem. 2012 Aug 7;10(29):5554-69
pubmed: 22710638
Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):192-196
pubmed: 32252196
Nutr Cancer. 2019;71(7):1214-1228
pubmed: 30955359
Expert Rev Mol Diagn. 2018 Mar;18(3):227-243
pubmed: 29424261
Methods Mol Biol. 2013;979:65-70
pubmed: 23397389
Clin Cancer Res. 1999 Oct;5(10):2971-7
pubmed: 10537367
J Med Chem. 1985 Mar;28(3):295-8
pubmed: 3973901
J Immunol. 2015 Sep 1;195(5):1995-2005
pubmed: 26238487
Cell Mol Life Sci. 2020 May;77(9):1745-1770
pubmed: 31690961
J Pharm Biomed Anal. 2017 Aug 5;142:42-48
pubmed: 28494338
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Anticancer Res. 2015 Apr;35(4):1967-76
pubmed: 25862849
Molecules. 2017 Dec 23;23(1):
pubmed: 29295519
Endocrinology. 2007 May;148(5):2363-74
pubmed: 17272396
Pathologe. 2018 Dec;39(Suppl 2):272-277
pubmed: 30327857
Cell Adh Migr. 2012 Nov-Dec;6(6):547-53
pubmed: 23257828
Anticancer Drugs. 2014 Sep;25(8):950-7
pubmed: 24949917
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Anticancer Agents Med Chem. 2018;18(14):2006-2009
pubmed: 30207246
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
pubmed: 2359136
Int J Cancer. 2006 Jan 15;118(2):290-301
pubmed: 16080193
Oncogene. 2005 Oct 20;24(46):6861-9
pubmed: 16007148
HPB (Oxford). 2013 Dec;15(12):944-50
pubmed: 23461776
Beilstein J Org Chem. 2011 Mar 21;7:338-45
pubmed: 21512602
Cancers (Basel). 2020 May 06;12(5):
pubmed: 32384792
Oncol Rep. 2013 Mar;29(3):917-24
pubmed: 23314174
Breast Cancer Res Treat. 2013 May;139(1):71-80
pubmed: 23609470
Anticancer Res. 2011 Dec;31(12):4359-67
pubmed: 22199301
J Enzyme Inhib Med Chem. 2019 Dec;34(1):838-852
pubmed: 30919701
Profiles Drug Subst Excip Relat Methodol. 2019;44:239-266
pubmed: 31029219
Oncol Lett. 2019 Apr;17(4):3981-3989
pubmed: 30930994
Sci Rep. 2016 Apr 15;6:24460
pubmed: 27080011
Cancer Lett. 2018 Jul 1;425:101-115
pubmed: 29608984
Breast Cancer Res Treat. 2007 May;102(3):253-61
pubmed: 17031577
Molecules. 2006 Jul 05;11(7):498-513
pubmed: 17971721
Mol Cancer Ther. 2012 Oct;11(10):2284-93
pubmed: 22902857
Br J Cancer. 2005 Oct 31;93(9):1005-10
pubmed: 16234819